Pathogenicity of Cryptococcus neoformans: Virulence factors and immunological mechanisms

Microbes and Infection

Volumn 1, Issue 4, 1999, Pages 293-301

  Rodrigues, Marcio L ^a   Alviano, Celuta S ^a   Travassos, Luiz R ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cryptococcus neoformans; Fungal pathogenesis; Host defense

Indexed keywords

VIRULENCE FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIAL VIRULENCE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL MENINGITIS; HOST RESISTANCE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

BACTERIA (MICROORGANISMS); FILOBASIDIELLA NEOFORMANS; FUNGI;

EID: 0032694180     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)80025-2     Document Type: Review

References (65)

1. Sanfelice F. Contributo alla morfologia e biologia dei blastomiceti che si sviluppano nei succhi di alcuni frutti. Ann. Igien. 4:1894;463-495.
2. Busse O. Über parasitäre zelleinschlüsse und ihre züchtung. Zentralbl. Bakteriol. 16:1984;175-180.
3. Buschke A. Über eine durch Coccidien Hervergerufene Krankheit des menschen. Dtsch. Med. Wochenschr. 21:1895;14.
4. Dromer F., Dupont B. The increasing problem of fungal infections in the immunocompromised host. J. Mycol. Méd. 6 Suppl. I:1996;1-6.
5. Mitchell T.G., Perfect J.R. Cryptococcosis in the era of AIDS: 100 years after the discovery of Cryptococcus neoformans, Clin. Microbiol. Rev. 8:1995;515-548.
6. Rodrigues M.L., Rozental S., Couceiro J.N.N., Angluster J., Alviano C.S., Travassos L.R. Identification of N-acetylneuraminic acid and its 9-O-acetylated derivative on the cell surface of Cryptococcus neoformans: Influence on fungal phagocytosis. Infect. Immun. 65:1997;4937-4942.
7. Edman J.C., Kwon-Chung K.J. Isolation of the URA5 gene from Cryptococcus neoformans var. neoformans and its use as a selective marker for transformation. Mol. Cell. Biol. 10:1990;4538-4544.
8. Kozel T. Virulence factors of Cryptococcus neoformans. Trends Microbiol. 3:1995;295-299.
9. Hatch T.F. Distribution and deposition of inhaled particles in respiratory tract. Bacteriol. Rev. 25:1961;237-240.
10. Wickes B.L., Mayorga M.E., Edman U., Edman J.C. Dimorphism and haploid fruiting in Cryptococcus neoformans: association with the α-mating type. Proc. Natl. Acad. Sci. USA. 93:1996;7327-7331.
11. Kwon-Chung K.L. Morphogenesis of Filobasidiella neoformans the sexual state of Cryptococcus neoformans, Mycologia. 68:1976;821-833.
12. Odom A., Muir S., Lim E., Toffaletti D.L., Perfect J.R., Heitman J. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 16:1997;2576-2589.
13. Lee S.C., Kress Y., Zhao M., Dickson D.W., Casadevall A. Cryptococcus neoformans survive and replicate in human microglia. Lab. Invest. 73:1995;871-879.
14. Levitz S.M., Dibenedetto D.J. Different stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans. Infect. Immun. 56:1988;2544-2551.
15. Diamond R.D., Root R.K., Bennett J.E. Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro, J. Infect. Dis. 125:1972;367-376.
16. + T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J. Exp. M. 175:1992;1685-1695.
17. + T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55:1994;35-42.
18. Huffnagle G.B., Boyd M.B., Street N.E., Lipscomb M.F. IL-5 is required for eosinophil recruitment crystal deposition and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J. Immunol. 160:1998;2393-2400.
19. Levitz S.M., Dupont M.P., Smail E.H. Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect. Immun. 62:1994;194-202.
20. Lee S.C., Dickson D.W., Brosnan C.F., Casadevall A. Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. J. Exp. M. 180:1994;365-369.
21. Murphy J.W., Cozad G.C. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5:1972;896-901.
22. Fidel P.L., Murphy J.W. Characterization of a cell population which amplifies the anticryptococcal delayed-type hypersensitivity response. Infect. Immun. 58:1990;393-398.
23. Fidel P.L., Murphy J.W. Effects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation. Infect. Immun. 57:1989;1158-1164.
24. Murphy J.W., Schafer F., Casadevall A., Adesina A. Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans. Infect. Immun. 66:1998;2632-2639.
25. Aguirre K., Havell A.E., Gibson G.W., Johnson L.L. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect. Immun. 63:1995;1725-1731.
26. Chen G.H., Curtis J.L., Mody C.H., Christensen P.J., Armstrong L.R., Toews G.B. Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J. Immunol. 152:1994;724-734.
27. Cross C.E., Collins H.L., Bancroft G.J. CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans. Immunology. 91:1997;289-296.
28. Mukherjee J., Scharff M.D., Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:1992;4534-4541.
29. Feldmesser M., Casadevall A. Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection. Front. Biosci. 3:1998;136-151.
30. Yuan R., Casadevall A., Spira G., Scharff M.D. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J. Immunol. 154:1995;1810-1816.
31. Yuan R., Casadevall A., Oh J., Scharff M.D. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. USA. 94:1997;2483-2488.
32. Vecchiarelli A., Retini C., Monari C., Casadevall A. Specific antibody to Cryptococcus neoformans alters human leukocyte synthesis and promotes T-cell proliferation. Infect. Immun. 66:1998;1244-1247.
33. Casadevall A., Mukherjee J., Devi S.J.N., Scheneerson R., Robbins J.B., Scharff M.D. Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 65:1992;1086-1093.
34. Hamilton A.J., Jeavons L., Hobby P., Hay R.J. A 34- to 38-kilodalton Cryptococcus neoformans glycoprotein produced as an exoantigen bearing a glycosylated species-specific epitope. Infect. Immun. 60:1992;143-149.
35. Varki A. Sialic acids as ligands in recognition phenomena. FASEB J. 1997;248-255.
36. Farhi F., Bulmer G.S., Tacker T.R. Cryptococcus neoformans. IV. The not-so encapsulated yeast. Infect. Immun. 1:1970;526-531.
37. Cherniak R. The soluble polysaccharides of Cryptococcus neoformans. Curr. Top. Med. Mycol. 2:1988;40-54.
38. Sundstrom J.B., Cherniak R. The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen. Infect. Immun. 60:1992;4080-4087.
39. Bulmer G.S., Sans M.D. Cryptococcus neoformans. III. Inhibition of phagocytosis. J. Bacteriol. 95:1968;5-8.
40. Fromtling R.A., Shadomy H.J., Jacobson E.S. Decreased virulence in stable acapsular mutants of Cryptococcus neoformans. Mycopathology. 79:1982;23-29.
41. Kwon-Chung K.J., Rhodes J.C. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect. Immun. 51:1986;218-223.
42. Chang Y.C., Kwon-Chung K.J. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol. Cell. Biol. 14:1994;4912-4919.
43. Kozel T.R., Highison B., Stratton C.J. Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect. Immun. 43:1984;574-579.
44. Buchanan K.L., Murphy J.W. What makes Cryptococcus neoformans a pathogen? Emerg. Infect. Dis. 4:1998;71-83.
45. Dong Z.M., Murphy J.W. Mobility of human neutrophils in response to Cryptococcus neoformans cells culture filtrate antigen and individual components of the antigen. Infect. Immun. 61:1993;5067-5077.
46. Dong Z.M., Murphy J.W. Intravascular cryptococcal culture filtrate (CneF) and its major component glucuronoxylomannan are potent inhibitors of leukocyte accumulation. Infect. Immun. 63:1995;770-778.
47. Dong Z.M., Murphy J.W. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J. Clin. Invest. 97:1996;689-698.
48. Dong Z.M., Murphy J.W. Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect. Immun. 65:1997;557-563.
49. Vecchiarelli A., Monari C., Retini C., Pietrella D., Palazzetti B., Pitzurra L., Casadevall A. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. Eur. J. Immunol. 28:1998;114-121.
50. Blackstock R., Casadevall A. Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen-presenting cells inhibit the T-supressor response and enhances delayed-type inhibits hypersensitivity and survival. Immunology. 92:1997;334-339.
51. Wong B., Perfect J.R., Breggs S., Wright K.A. Production of hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect. Immun. 58:1990;1664-1670.
52. Chaturvedi V., Flynn T., Niehaus W., Wong B. Stress tolerance and pathogenic potential of a mannitol mutant of Cryptococcus neoformans. Microbiology. 142:1996;937-943.
53. Chaturvedi V., Wong B., Newman S.L. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. J. Immunol. 156:1996;3836-3840.
54. Williamson P.R. Laccase and melanin in the pathogenesis of Cryptococcus neoformans. Front. Biosci. 2:1997;99-107.
55. Salas S., Bennett J.E., Kwon-Chung K.J., Perfect J.R., Williamson P.R. Effect of the laccase gene CNLAC1 on virulence of Cryptococcus neoformans. J. Exp. M. 184:1996;377-386.
56. Torres-Guerrero H., Edman J.C. Melanin deficient mutants of Cryptococcus neoformans. J. Med. Vet. Mycol. 32:1994;3-13.
57. Nosanchuk J.D., Casadevall A. Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide melanin and monoclonal antibody binding. Infect. Immun. 65:1997;1836-1841.
58. Chen S.C.A., Muller M., Zhou J.Z., Wright L.C., Sorrel T.C. Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J. Infect. Dis. 175:1997;414-420.
59. Jacobson E.S., Jenkins N.D., Todd J.M. Relationship between superoxide dismutase and melanin in a pathogenic fungus. Infect. Immun. 62:1994;4085-4086.
60. Chen L., Pirofski L., Casadevall A. Extracellular proteins ofCryptococcus neoformansand host antibody response, Infect. Immun. 65:1997;2599-2605.
61. Alspaugh J.A., Perfect J.R., Heitman J. Cryptococcus neoformans mating and virulence are regulated by the G-protein α subunit GPA1 and cAMP. Genes Dev. 11:1997;3206-3217.
62. Lee S.C., Casadevall A., Dickison D.W. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am. J. Pathol. 148:1996;1267-1274.
63. + T cell-dependent acquired state of immunity that protects the brain against Cryptococcus neoformans. J. Immunol. 152:1994;2344-2350.
64. Dobrick P., Miksits K., Hahn H. L3T4 (CD4)- Lyt-2 (CD8)- and Mac-1 (CD11-b)-phenotypic leukocytes in murine cryptococcal meningoencephalitis. Mycopathologia. 131:1995;159-166.
65. Aguirre K.M., Johnson L.L. A role for B cells in resistance to Cryptococcus neoformans in mice. Infect. Immun. 65:1997;525-530.